OSR Holdings Inc (OSRH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OSR Holdings Inc (OSRH) has a cash flow conversion efficiency ratio of -0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.15 Million) by net assets ($134.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OSR Holdings Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how OSR Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OSRH current and long-term liabilities for a breakdown of total debt and financial obligations.
OSR Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OSR Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PROBIOTIX HEALTH LS-05
F:X90
|
N/A |
|
CLASS 1 NICKEL+TECH.LTD
F:77C
|
0.076x |
|
Supermarket Income REIT PLC
LSE:SUPR
|
0.025x |
|
Gold By Gold
PA:ALGLD
|
0.083x |
|
KGW Group Berhad
KLSE:0282
|
0.119x |
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
0.032x |
|
Cyabra, Inc. Common Stock
NASDAQ:CYAB
|
0.065x |
|
Gauzy Ltd. Ordinary Shares
NASDAQ:GAUZ
|
-0.185x |
Annual Cash Flow Conversion Efficiency for OSR Holdings Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of OSR Holdings Inc from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see how much is OSR Holdings Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.49 Million | $-2.19 Million | 0.337x | +1439.86% |
| 2023-12-31 | $32.52 Million | $-818.77K | -0.025x | -122.30% |
| 2022-12-31 | $-37.51K | $-4.24K | 0.113x | -48.08% |
| 2021-12-31 | $-2.12K | $-461.00 | 0.217x | +101.08% |
| 2020-12-31 | $1.19K | $-23.81K | -20.044x | -- |
About OSR Holdings Inc
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatme… Read more